Figure 6 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

Le résumé fourni par la source

Synergy of combined dasatinib and trametinib in BRAFG469V-driven DIPG cells. A, Cell viability matrices for ICR-B169 parental (gray) and trametinib-resistant clones T1 (MEK2I115N, pink), (T3 MEK1I141S, purple), and T6 (MEK1K57N, red), treated with distinct combinations of dasatinib (y-axes) and trametinib (x-axes) ranging from 0 to 10 μmol/L. A heat map is overlaid to the proportions of viable cells remaining, colored according to the key provided from 1.0 (black, all cells) to 0 (red, no viable cells). B, Excess above BLISS matrices for ICR-B169 parental and trametinib-resistant clones treated with distinct combinations of dasatinib (y-axes) and trametinib (x-axes) ranging from 0 to 10 μmol/L. A heat map is overlaid to the excess score, colored according to the key provided from 0.4 (red, enhanced effects) to 0 (green, no difference). C, BLISS synergy maps for ICR-B169 parental and trametinib-resistant clones treated with distinct combinations of dasatinib (y-axes) and trametinib (x-axes) ranging from 0 to 10 μmol/L. The heat map represents the δ score colored according to the key provided from 30 (red, high degree of synergy) to −30 (green, antagonism).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.